Company profile for Quince Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Quince Therapeutics is focused on advancing innovative precision therapeutics targeting debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote more rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Quince’s discov...
Quince Therapeutics is focused on advancing innovative precision therapeutics targeting debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote more rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Quince’s discovery pipeline is positioned for rapid expansion across multiple skeletal therapeutic indications to address underserved therapeutic areas.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
601 Gateway Blvd, Suite 1250, South San Francisco, California 94080
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251215328276/en/Quince-Therapeutics-Announces-Last-Patient-Last-Visit-in-Phase-3-NEAT-Clinical-Trial-in-Patients-with-Ataxia-Telangiectasia

BUSINESSWIRE
15 Dec 2025

https://www.businesswire.com/news/home/20251210188416/en/Quince-Therapeutics-Announces-Publication-of-Use-of-eDSP-in-Early-Stage-Clinical-Studies-in-Pulmonary-and-Inflammatory-Bowel-Disorders

BUSINESSWIRE
10 Dec 2025

https://www.businesswire.com/news/home/20251124942104/en/Quince-Therapeutics-to-Participate-at-Investor-Events-in-December-2025

BUSINESSWIRE
24 Nov 2025

https://www.businesswire.com/news/home/20251112266523/en/Quince-Therapeutics-Provides-Business-Update-and-Reports-Third-Quarter-2025-Financial-Results

BUSINESSWIRE
12 Nov 2025

https://www.businesswire.com/news/home/20251021956399/en/Quince-Therapeutics-Announces-Positive-iDSMB-Review-for-eDSP-in-Pivotal-Phase-3-NEAT-Clinical-Trial-in-Ataxia-Telangiectasia

BUSINESS WIRE
10 Nov 2025

https://www.pharmiweb.com/press-release/2025-10-09/quince-therapeutics-presents-data-from-patient-reported-walking-capacity-in-children-with-ataxia-tel

PHARMIWEB
09 Oct 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty